Cara Therapeutics to Present at the 27th European Academy of Dermatology & Venereology Congress
September 05 2018 - 4:01PM
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company
focused on developing and commercializing new chemical entities
designed to alleviate pruritus and pain by selectively targeting
peripheral kappa opioid receptors, today announced a presentation
at the 27th European Academy of Dermatology & Venereology
Congress (EADV), to be held September 12-16, 2018 in Paris.
Details for the presentation are as follows:
Oral Presentation: |
|
|
Title: |
"Clinically Meaningful
Reduction of Itch and Improvement in Multiple Quality of Life
Measures in Hemodialysis Patients with Moderate-to-Severe Pruritus
Following Treatment with Difelikefalin” |
Date /
Time: |
Thursday, September 13,
2018, 15:00 - 16:30 CET |
Presenter: |
Frédérique Menzaghi,
Ph.D., Senior Vice President, Research & Development, Cara
Therapeutics |
For information about EADV, visit https://eadvparis2018.org.
About Cara
Therapeutics
Cara Therapeutics is a clinical-stage
biopharmaceutical company focused on developing and commercializing
new chemical entities designed to alleviate pruritus and pain by
selectively targeting peripheral kappa opioid receptors. Cara is
developing a novel and proprietary class of product candidates, led
by KORSUVATM (CR845/difelikefalin), a first-in-class kappa opioid
receptor agonist that targets the body's peripheral nervous system,
as well as certain immune cells. In Phase 2 trials, KORSUVA
injection has demonstrated statistically significant reductions in
itch intensity and concomitant improvement in quality of life
measures in hemodialysis patients suffering from moderate-to-severe
chronic kidney disease-associated pruritus (CKD-aP). KORSUVA
is currently being investigated in global Phase 3 trials in
hemodialysis patients with CKD-aP. Additionally, in a recently
completed Phase 2/3 trial in post-operative patients, I.V.
CR845/difelikefalin has demonstrated reduction in
moderate-to-severe pain, while also reducing the incidence and
intensity of nausea and vomiting throughout the post-operative
period.
The FDA has conditionally accepted KORSUVA™ as
the trade name for difelikefalin injection. CR845/difelikefalin is
an investigational drug product, and its safety and efficacy have
not been fully evaluated by any regulatory authority.
INVESTOR CONTACT:Michael SchaffzinStern
Investor Relations212-362-1200michael@sternir.com
MEDIA CONTACT:Annie Starr6 Degrees973-415-8838
astarr@6degreespr.com
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Apr 2023 to Apr 2024